ABSTRACT
1
For most subtypes, its pathogenesis is directly related to chronic infection by high-risk human papillomavirus (HPV) in susceptible hosts. 2 There are many different histologic types of cervical carcinoma, the most common being squamous cell carcinoma (SCC; 65%-80% of all cases), followed by adenocarcinoma (15%-25%). 3 Other less frequent histologies include adenosquamous carcinoma, neuroendocrine tumors, carcinosarcoma, and nonepithelial neoplasms.
Lymphoepithelioma-like carcinoma (LELC) constitutes a rare subtype, best classified as a variant of SCC in the cervix. LELCs are classically seen in the nasopharynx, but a broad distribution across other anatomic sites, such as lung, skin, gastrointestinal tract, and urinary bladder, also has been reported. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] In the nasopharynx, several studies have shown the presence of Epstein-Barr virus (EBV) latent genes in tumor cells, which indicates a strong correlation between EBV infection and LELC carcinogenesis. 14, 15 However, in the cervix, the pathogenesis of LELC is still not entirely clear. While most evidence suggests that HPV plays a role in its etiology, [16] [17] [18] limited data (predominantly from the Asian population) hypothesize that LELC may be an EBV-driven process. 19, 20 A few studies, however, did not find any association with HPV or EBV infection. [21] [22] [23] [24] The goal of this study was to evaluate a series of cases of cervical LELCs to better describe the most common histologic and immunophenotypic findings, as well as to investigate the possible presence of high-risk HPV and/or EBV genome in tumor cells.
Materials and Methods
We retrospectively searched our surgical pathology database for cases of LELC involving the cervix, from a 15-year period (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) (2017) , following institutional review board approval. The slides were reviewed and the diagnosis confirmed by two pathologists (A.P. and M.N.). Immunohistochemistry (IHC) for p63 (clone 4A4, ready to use; Biocare, Pacheco, CA), p16 (clone E7, ready to use; Roche, Indianapolis, IN), human leukocyte antigen-D related (HLA-DR; clone LN3, 1:400; Biogenex, Fremont, CA), and B-cell lymphoma 2 (BCL-2; clone BCL2-100, ready to use; Leica, Chicago, IL) was performed on 4-μm-thick formalin-fixed, paraffin-embedded (FFPE) sections.
We investigated the mismatch repair (MMR) protein status using IHC for MLH1 (clone ES05, ready to use; Leica), PMS2 (clone MRQ-28, ready to use; Cell Marque, Rocklin, CA), MSH2 (clone 25D12, ready to use; Leica), and MSH6 (clone 44MAB, ready to use; Cell Marque). PD-L1 staining by IHC ((PD-L1; clone 22C3, Dako, Carpinteria, CA) was also performed and any degree of membranous labeling was considered positive, with further assessment of the percentage of immunoreactive tumor cells (<1%, 1%-49%, and ≥50%).
In situ hybridization (ISH) for high-risk (HR)-HPV (covering subtypes 16/18/33; Leica) and EBV (EpsteinBarr encoding region [EBER]; Leica) were performed in 4-μm-thick FFPE sections.
HPV genotyping was obtained through polymerase chain reaction (PCR), using type-specific primers for early protein genes (E5-E7) in FFPE tumors. Six HR types (16, 18, 31, 33, 45, 58) and one low-risk type (6/11) were tested by fragment analysis. The PCR testing was performed by NeoGenomics Laboratories (Aliso Viejo, CA) .
Nine cases of "conventional" SCC of the cervix were used as control for immunohistochemical and ISH studies, with the exception of MMR and PD-L1, which were only investigated in LELC cases.
All tests were carried out on a Leica BOND III automated stainer.
Clinical data were abstracted from the patients' medical records, including age, date of diagnosis, treatment received, and follow-up information. Pathologic data included size of tumor, presence or absence of lymphovascular space invasion, grade of tumor, and stage.
Results
Eight cases of cervical LELC were obtained. They corresponded to tumors occurring in patients from 26 to 81 years of age (median, 54 years), none of which included patients of Asian descent. The cases consisted of three biopsy specimens (including one loop electrosurgical excision procedure) and five resection specimens (four radical hysterectomies and one simple hysterectomy). In the three biopsy-only patients, two patients were treated with chemoradiation therapy due to advanced-stage disease, and one was lost to follow-up after recommendation for adjuvant therapy. Most patients (six of eight) presented with early stage disease. Two cases were classified with International Federation of Gynecology and Obstetrics (FIGO) stage IA2, two patients with stage IB1, and two with stage IB2. One case with IB2 disease had positive pelvic and para-aortic lymph nodes. One patient had stage IIIA disease. Tumor size ranged from 0.4 cm to 7 cm at time of diagnosis ❚Table 1❚.
Morphologically, all tumors showed poorly differentiated morphology with islands of neoplastic cells containing vesicular nuclei, prominent nucleoli, and eosinophilic or amphiphilic cytoplasm ❚Image 1❚. No keratinization was present. Some areas contained tumor cells singly dispersed. The most noticeable characteristic was the presence of a dense lymphocytic infiltrate within and/ or around the tumor nests.
One case had two distinct components that consisted of LELC and conventional SCC, the former spanning approximately 80% of the tumor. The foci were adjacent to each other but without merging of the components. Lymphovascular invasion was present in four of eight cases.
Immunohistochemically, all tumors (eight of eight) stained positive for p16 (in a diffuse pattern), p63, and HLA-DR. Two of eight cases were also positive for BCL-2. By ISH, six of eight tumors were positive for HR-HPV ISH, while all cases were negative for EBER. When combining ISH and PCR results, seven tumors were positive for HPV ❚Image 2❚ and ❚Table 2❚. There were three cases of HPV 16, two cases of HPV 18, and one case of HPV 33. One HPV-PCR-positive case was negative by ISH, while one ISH-positive case was negative by PCR.
The control cases (conventional SCC) showed p63 and p16 labeling in all cases (nine of nine), HLA-DR was positive in four of nine, BCL-2 in five of nine, and ISH for HR-HPV in the majority (six of nine). Two of nine cases were equivocal for HR-HPV ISH, and one of nine was negative. No cases were positive for EBER (zero of nine).
MMR Status and PD-L1 Expression
All tumors showed intact expression of all four MMR proteins by IHC. Interestingly, we found that all except for one tumor expressed PD-L1, with half of them in a patchy distribution corresponding to a tumor proportion score (percentage of neoplastic cells staining among the entire tumor cell population) in the range of 1% to 49%. The three remaining positive cases showed more than 50% staining.
Clinically, one patient progressed following chemoradiation with intra-abdominal disease approximately 9 months after initial diagnosis. The second patient to receive chemoradiation has only recently completed treatment. Two patients were lost to follow-up. The remaining four patients are currently free of disease (range, 9-24 months).
Discussion
LELC, considered by the World Health Organization as a variant of nonkeratinizing SCC, 25 is very rare in the cervix. It estimated that less than 1% of cervical cancers are LELC. 26 The classic site of origin for LELC is the nasopharynx. The first reports of such a neoplasm in that anatomic site were published over a century ago by Regaud 27 and Schminke. 28 The tumors were initially described as having loose epithelial cells admixed with a very rich lymphocytic infiltrate, resembling a "lymphosarcoma." 29 Subsequently, the presence of the EBV genome in tumor cells was demonstrated by different techniques in many studies. 15, [30] [31] [32] In other locations such as lung, gastrointestinal tract, skin, and breast, the role of EBV is still not well defined, with few publications suggesting a relationship with the virus, while several other studies do not support such an association. 11, [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] Given its rarity, data regarding the relationship between HPV and/or EBV infection and pathogenesis of cervical LELC are limited and similarly conflicting. In a study involving Asian patients, the authors reviewed a cohort of 15 cases and found that the EBV gene sequence in tissue samples from patients with LELC was more frequent than that in control cases showing SCC (73.3% vs 26.7%). 19 On a different case series, both HR-HPV and EBV DNA were present in carcinoma cells. 20 Few studies have found the presence of HPV (16, 18, 45) by PCR but no EBV in the cervical LELC, 16, 17 while others did not establish a relationship with the viruses. 21, 23, 24, 49 Also in the gynecologic tract, two cases involving the vagina were described to be associated with HPV (without specifying the genotype) in a recent study. 50 In the present study, seven of eight LELCs were HPV related, with the most frequent subtype being HPV 16 (3), followed by HPV 18 (2) and HPV 33 (1). This pattern is ❚Image 1❚ Examples of four cases from our study. Low-power (×100; A) and mid-power (×200; B) views showing sheets of tumor cells with syncytial arrangement, admixed with a lymphocyte-rich stroma. On high power (×400; C, D), the cells demonstrate eosinophilic cytoplasm, vesicular nuclei, and indistinct cell membranes (all images are H&E). consistent with the most common HPV strains seen in cervical cancer in general. Interestingly, we had two discordant cases between ISH and PCR results. The first discordant case (ISH+, PCR-) is attributed to the near absence of tumor cells in the material submitted for PCR, while the second discrepant case (ISH-, PCR+) is interpreted as a result of the higher sensitivity of PCR testing. Nevertheless, both cases had strong p16 staining by IHC, which supports the initial impression of an HPV-driven process.
BCL-2 is a protein that confers a selective growth enhancement to the EBV-infected B cells. 51 Detection of BCL-2 via IHC has been described as a sensitive marker in tumors having the LELC phenotype, 35, 52, 53 but large studies with regard to its specificity are lacking. HLA-DR is part of the major histocompatibility complex class II family of antigen presentation molecules. This protein is normally expressed on antigen-presenting cells such as monocytes, dendritic cells, and B cells. 54 This expression, however, can also be seen in tumor cells, including in LELCs. [54] [55] [56] As shown in our study, despite some reports showing some utility of HLA-DR and BCL-2 IHC in the diagnosis of LELC, we found that HLA-DR is sensitive (all cases LELC were immunoreactive) but not specific for separating this tumor from conventional SCC (four of nine cases positive). With regard to BCL-2, we did not find this marker to be sensitive or specific for the diagnosis of LELC (two of eight LELCs vs five of nine SCCs; P = .33). Hence, it is possible that the expression of BCL-2 may be related to EBV-driven tumors rather than to LELC histology per se.
Tumors with microsatellite instability tend to demonstrate a brisk tumoral and peritumoral inflammatory infiltrate, which led us to investigate the MMR status in our LELC cases. All tumors showed intact protein expression, suggesting microsatellite stability. In addition, given the emerging data supporting the overexpression of PD-L1 in various neoplasms and the potential therapeutic benefits using checkpoint inhibitors such as pembrolizumab, we decided to perform PD-L1 IHC in the LELCs, and the results were interesting. Seven of eight cases showed PD-L1 overexpression in neoplastic cells, with three tumors demonstrating more than 50% of positive cells ❚Image 3❚. These patients with PD-L1 overexpression may be candidates for checkpoint inhibition in the future. Clinical trials with single-agent checkpoint inhibitors in cervical cancer are ongoing.
On the basis of histology, the differential diagnosis of cervical LELC includes SCC with an exuberant lymphocytic infiltrate, adenosquamous carcinoma of "glassy cell" type, and large cell lymphomas.
SCC with a dense surrounding lymphocytic population differs from LELC by lacking the vesicular nuclei and syncytial appearance of LELC. Although SCC can occasionally demonstrate dispersion of single cells, this pattern is unusual, and when groups of cells are present, they frequently show prominent borders that are not seen in LELC. Keratinization may also be present in SCC but not in LELC.
Glassy cell carcinomas (GCCs) tend to occur in patients of young age. Despite limited demographic data available for cases of LELC, our review showed a relatively older patient population (median age, 54 years). With regard to morphology, GCCs have a higher mitotic activity, display an abundant eosinophilic cytoplasm with distinct cell membranes, and occasionally can show the presence of glands. Furthermore, the inflammation is usually composed of eosinophils and plasma cells rather than lymphocytes.
Lymphomas involving the cervix are rare. In tumors on which the cells are only singly disposed and lacking an epithelial phenotype, positive IHC for keratin is helpful in the diagnosis of LELC.
The prognosis of cervical LELC is still poorly understood. In our cohort, six (75%) of eight patients had early stage (FIGO I or II) disease at the time of diagnosis. However, the number of cases in our series is limited, and more studies with longer clinical follow-up are needed to definitively characterize the behavior of LELC.
Conclusions
As we better understand the pathogenesis of cervical carcinoma, including knowledge of tumors that are HPV (approximately 90%) vs non-HPV related (eg, gastric, a subset of intestinal-type adenocarcinomas, mesonephric carcinomas, and clear cell carcinomas), studies describing less common histologic subtypes are important to expand our understanding of cervical tumorigenesis.
Cervical LELC is a rare neoplasm with unique morphology and immunohistochemical profile. This study showed that in contrast to LELC occurring in other anatomic sites (eg, nasopharyngeal), cervical LELCs are associated with HPV and do not appear to be related to EBV.
